Pioneers in AOX biology.
Driving the development of next generation antifungal agents to improve human and crop health
AlternOx Scientific Ltd is a newly established bio-pharma company developing novel, proprietary inhibitors of the enzyme alternative oxidase (AOX) to treat a wide range of multi-drug and multi-compound resistant species of fungi that now threaten human health and food security worldwide.
The global market for new and improved fungicides is growing every day. Fungal pathogens with the potential to devastate food crops or spread through human patient populations have been developing greater resistance to antifungal treatments over the decades. The situation demands a novel approach to secure food production and protect our health.
AlternOx Scientific has developed an expanding library of AOX targeting antifungal compounds based on pioneering research by Prof. Tony Moore at the University of Sussex. This unique solution holds the key to the next generation of smarter antifungal remedies.
Change the prognosis for fungal disease
An urgent global medical challenge is to overcome the burgeoning resistance to antifungal therapies.
Just as we have seen with growing antibiotic resistance in recent years, endemic fungal diseases such as invasive candidiasis - and especially C. auris infections - are becoming harder to treat with the existing clinical toolkit. Infections by these life-threatening fungal pathogens are becoming more common and have been exacerbated by Covid-19 in ICU situations.
In trials with partners including Public Health England novel, target designed, AOX inhibitors developed by AlternOx have demonstrated the potential to combat fungal resistance – even against all known resistant strains of C. auris.
With the unique platform of enabling AOX technologies developed by AlternOx, the opportunity now exists to bring these promising new treatments to market.
Meet the team
Our experienced and committed management team boasts an international authority on the science of the alternative oxidase, significant commercial expertise in bringing new biotech innovations to market, and a stellar supporting cast of industry advisors.
Ashley Cooper is an experienced life science CEO with 33 years’ commercial experience spanning the animal health, veterinary/clinical diagnostic, food diagnostic, pharmaceutical and biotech/biomedical sectors. He has managed the development, launch and marketing of complex life science products and services in Europe, South Africa, USA and Asia. Ashley’s early career was spent with GSK’s animal health division and IDEXX Laboratories in its formative years, during which he was responsible for the establishment of its highly successful UK subsidiary. Much of his career however has been spent in the establishment of start-up and early stage life science companies, of which 12 have been in the position of either Vice President or Chief Executive Officer (on a full time, part time or interim basis). Since 2000 all of these ventures have involved the commercialisation of ex-academic IP and the establishment of academic spin out companies.
Ashley Cooper – Chief Executive Officer
Publications and Press
+44 (0)1494 488 454 | a.cooper@alternox.com
